News
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease ...
Pfizer and Johnson & Johnson are two healthcare giants. Both have a solid earnings growth outlook, but they differ in terms of valuation, as well as in the dividend yields they offer right here.
Johnson & Johnson expects to make $2.5 billion in revenue from its COVID-19 vaccine in 2021. That's a drop in the bucket for the mammoth business, which generated more than $80 billion in revenue ...
Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday ...
Some consumers have been wary of the Johnson & Johnson vaccine because its overall efficacy in clinical trials was 66% compared with about 95% for the Moderna and Pfizer vaccines.
The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15 , ...
While the Pfizer and Moderna shots have a lot in common, the new Johnson & Johnson vaccine has some notable differences. A fourth COVID-19 inoculation, the AstraZeneca vaccine, may also soon be ...
CDC recommends Pfizer, Moderna vaccines over Johnson & Johnson, citing rare blood-clot issue Nine deaths, several dozen cases, have been confirmed in connection with the vaccine. Updated December ...
Pfizer and Johnson & Johnson’s manufacturing is accelerating, while Moderna’s is staying stagnant. Utah will receive 93,600 doses of the Pfizer vaccine this week, compared to 74,880 last week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback